SCHEMBL26684281

SCHEMBL26684281

O/N=C/c1ccc(F)c(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ VCP P55072 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MAOA P21397 4/20 0.41
▸ MAOB P27338 4/20 0.41
▸ NPFFR1 Q9GZQ6 3/20 0.41
▸ NPFFR2 Q9Y5X5 3/20 0.41
▸ NPC1 O15118 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ ACHE P22303 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MGAM O43451 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30667977 1.00 SMN1; SMN2 (0.46) SMN1; SMN2RAB9AVCPALDH1A1KDM4E
SCHEMBL3520908 0.84 ALDH1A1 (0.46) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL3520904 0.84 ALDH1A1 (0.46) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL2472101 0.81 ALDH1A1 (0.50) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL9351215 0.81 NPFFR1 (0.58) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL9351222 0.81 NPFFR1 (0.58) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL2472098 0.81 ALDH1A1 (0.50) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL2474936 0.81 ALDH1A1 (0.50) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
Hydrochloric Acid SCHEMBL28115143 0.79 PLA2G7 (0.49) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL1304439 0.78 SMN1; SMN2 (0.47) SMN1; SMN2RAB9AALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 — — US disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 — — EP disclosed
WO-2023217906-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB SMN1; SMN2 3383/4885RAB9A 3056/4885VCP 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback